NMRD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NMRD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Nemaura Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $19.64 Mil. Nemaura Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nemaura Medical's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-17.83 Mil. Nemaura Medical's debt to equity for the quarter that ended in Dec. 2023 was -1.10.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nemaura Medical's Debt-to-Equity or its related term are showing as below:
During the past 10 years, the highest Debt-to-Equity Ratio of Nemaura Medical was 41.18. The lowest was -5.28. And the median was 0.46.
The historical data trend for Nemaura Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nemaura Medical Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | - | - | 2.98 | 41.18 | -1.70 |
Nemaura Medical Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Debt-to-Equity | Get a 7-Day Free Trial | -2.04 | -1.70 | -1.19 | -1.32 | -1.10 |
For the Medical Devices subindustry, Nemaura Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nemaura Medical's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Nemaura Medical's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (16.943 | + | 3.088) | / | -11.814 | |
= | -1.70 |
Nemaura Medical's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (19.643 | + | 0) | / | -17.827 | |
= | -1.10 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nemaura Medical (OTCPK:NMRD) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Nemaura Medical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Bashir Timol | director, 10 percent owner, officer: Chief Business Officer | C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
Chowdhury Dewan Fazlul Hoque | director, 10 percent owner, officer: CEO & President | CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ |
Salim Natha | director | LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF |
Justin James Mclarney | officer: Chief Financial Officer | C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
Sufyan Ismail | 10 percent owner | C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
Thomas Peter Moore | director | C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
Timothy Christopher Johnson | director | C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019 |
Iain Anderson | officer: CFO | LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF |
Kathryn Farrar | officer: Director of Finance | C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
Julie Pomeroy | officer: Director of Finance | C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
Richard Toon | officer: Technical & Bus. Dev. Manager | C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 11-04-2022
By Marketwired • 09-13-2023
By Marketwired • 07-14-2023
By Marketwired • 08-17-2023
By Value_Insider Value_Insider • 11-11-2022
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 07-08-2022
By Marketwired • 08-11-2023
By Value_Insider Value_Insider • 11-29-2022
By sperokesalga sperokesalga • 02-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.